Assertio Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 05:13 pm EST
Share
Assertio Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 35.63 million compared to USD 34.21 million a year ago. Net loss was USD 279.54 million compared to net income of USD 4.17 million a year ago. Basic loss per share from continuing operations was USD 3.42 compared to basic earnings per share from continuing operations of USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 3.42 compared to diluted earnings per share from continuing operations of USD 0.08 a year ago.
For the nine months, revenue was USD 119.08 million compared to USD 105.88 million a year ago. Net loss was USD 274.56 million compared to net income of USD 21.07 million a year ago. Basic loss per share from continuing operations was USD 4.35 compared to basic earnings per share from continuing operations of USD 0.45 a year ago. Diluted loss per share from continuing operations was USD 4.35 compared to diluted earnings per share from continuing operations of USD 0.42 a year ago.
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
ASSERTIO HOLDINGS, INC. 
